Hey Larry, good to see you here. I don't frequent the board much have been involved with corr for awhile. At current price picked up more.
to up my holdings in gthp. Only negative I find is the market is not paying attention (maybe it is and not ready to act). Realistically the market wants results and that will only happen when the FDA makes it's announcement and earnings justifies the $$. Sure there is risk but the reward seems justified to up the $$$$$ investment, after all a double is not something to sneeze at for starters.
If interested just type in search "prop think gthp" for that very enlightening article.
thanks to tonoos for passing the article alert to us "new" investors.
keep the faith and you shall be rewarded.
ok, maybe I over stepped my bounds when I said the" board is full of" I should have been more specific. My apologies.
You guys have been here way longer than me and are more attuned to the ins and outs of gthp and I give you credit to that. However, nothing wrong in conversing about a subject near and dear to our hearts i.e. making a few $$$ and the more the merrier.
I don't dip in say my 2 cents and skip out with a skimpy $100.00 profit, I am here until all the cards are dealt and the hand is played. If I rehash old news or ask worn out questions please give me the benefit of the doubt and go easy. In the end all that matters is gthp
growing up and becoming more valuable to it's share holders.
New news is good news and looks like exciting times are coming.
Sentiment: Strong Buy
the mini cvi etf (cvi, uan and uan) are moving in unison (for now?) we literally went months without this
type of coordinated move. I like it but I would like to know the fundamentals behind the (coordinated?) move.
I literally do not know, not to say $.52 is a cheap price but it sure does not sound expensive considering the potential of Luviva. I like companies with fda submissions that pose a very real possibility of validation. There are so many diseases that technology is catching onto making inroads all the time. Example is edap (I have mentioned before) they locate localized prostate cancer
and toast the cancer cells with heat, no radical surgery no radiation, sounds like a winner to me just as Luviva does for women the edap system does for men.
If the upcoming presentation can shed some light on how accurate Luviva is and keep the cost reasonable we have a winner somewhere down the road, until then one has to place his bets and wait. The word "wait" looms large when playing in the biggest casino in the world.
I want it now, can't wait, babbling incoherently crybaby's. Way to funny. Refer to the past article about
unmet needs of women around the world and maybe patience will be rewarded.
"We believe that the results of this new clinical study, to be presented to the leading cervical cancer experts from around the world, will further validate LuViva’s future role in improving the diagnosis of cervical cancer in women across the globe", anybody who doesn't believe the company knows what the presenters will allude too? I am sold on the possibilities of Luviva and have put my $$$$$$$ in the company and am patient enough to wait and feel I have made a good investment.
Sentiment: Strong Buy
again, March 17th is approaching day by day, a day of reckoning be it positive or negative.
I am on the positive side......tick tock tick tock.
No time for that, the 17th is coming and then the rubber hits the road, the head buts begin between the bulls and the bears should be over and earnings are established for abstral.. For now it's "I say, you say" and $$$ are changing hands. We know sales are happening based on last quarter and no reason for it to decrease just increase.
over $4 mill on abstral sales = somewhat static pps
$5 mill =great response in the pps
under $4 mill and the shorts shout I told you so.
$6 mill and over "oh boy" the longs are super smileing.